2009 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2014 (v1)Publication
Background: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy...
Uploaded on: March 27, 2023